Quarterly report pursuant to Section 13 or 15(d)

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

v3.24.3
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
9 Months Ended
Sep. 30, 2024
Cash and Cash Equivalents [Abstract]  
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

3. CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

 

The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within 90 days from the date of purchase to be cash equivalents. At September 30, 2024 and December 31, 2023, cash equivalents were comprised of money market funds and corporate debt securities with maturities less than 90 days from the date of purchase.

 

Restricted cash as of September 30, 2024 included security for a stand-by letter of credit issued in favor of a landlord for $0.7 million of which $0.3 million was classified in current assets and $0.4 million was classified in noncurrent assets as of September 30, 2024.

 

Cash, cash equivalents, and restricted cash consist of the following (in thousands):

 

 

 

September 30, 2024

 

 

December 31, 2023

 

Cash

 

$

3,535

 

 

$

4,029

 

Cash equivalents

 

 

15,888

 

 

 

9,695

 

Cash and cash equivalents

 

 

19,423

 

 

 

13,724

 

 

 

 

 

 

 

Restricted cash, current

 

 

285

 

 

 

192

 

Restricted cash, noncurrent

 

 

385

 

 

 

478

 

Restricted cash

 

 

670

 

 

 

670

 

Total cash, cash equivalents, and restricted cash shown in the statement of cash
   flows

 

$

20,093

 

 

$

14,394

 

 

As of September 30, 2024, the Company’s cash and cash equivalents held in the U.S. was approximately $16.2 million and approximately $3.2 million of cash was held in its subsidiaries in the United Kingdom and Australia. As of December 31, 2023, all of the Company’s cash was held in the U.S., except for approximately $3.8 million of cash which was held in its subsidiaries in the United Kingdom and Australia.

 

Our foreign subsidiaries in the United Kingdom and Australia may qualify for refundable research and development tax credits in the form of cash that were earned on certain research and development expenses incurred primarily outside of the U.S. The Company received $0 and $2.5 million in refundable research and development credits from foreign tax authorities for the three and nine months ended September 30, 2024, respectively. The Company received $0.1 million in refundable research and development credits from foreign tax authorities for the three and nine months ended September 30, 2023. These amounts are recorded in other income (expense), net. No future conditions impact the recognition of these tax credits.